id	author	title	date	pages	extension	mime	words	sentence	flesch	summary	cache	txt
dpc-2201	Sadeghi, Sara; Goodarzi, Azadeh	Various Applications of Tofacitinib and Ruxolitinib (Janus Kinase Inhibitors) in Dermatology and Rheumatology: A Review of Current Evidence and Future Perspective	2022	7	.pdf	application/pdf	4947	423	59	Based on records in the reviewed studies, both medications had acceptable safety profiles; however, physicians are recommended to outweigh the risks and benefits of such treatments for each specific condition. Paik et al reviewed tofacitinib efficacy in two well-designed parallel RCTs (phase 3) in PsA patients: the OPAL Broaden with 442 patients for 12 months and the OPAL Beyond with 394 patients for six months.	cache/dpc-2201.pdf	txt/dpc-2201.txt